← Leaderboards
Brett D Welch
Navigen, Inc.
$8,974,527
Attributed
$9,949,375
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2012–19$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$9,949,375 · 7
By mechanism
R44$5,887,200 · 2
R43$2,112,478 · 4
R01$1,949,697 · 1
Top collaborators
- Alan L Mueller3 shared
Most similar at Navigen, Inc.
Same institution · by research overlap
- Daniel A Wettstein$1,649,973
- James Nicholas Francis$149,973
Others in their field
Top investigators on “Immunogenicity”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,963,650
- Lawrence Corey · Fred Hutchinson Cancer Center$378,262,806
- Barton F Haynes · Duke University$364,422,244
- Dennis R. Burton · Scripps Research Institute$311,593,259
- Peter B. Gilbert · Fred Hutchinson Cancer Center$200,471,907
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$172,054,560
Research focus
ImmunogenicityPeptide HydrolasesDesignAffinityIn VivoPeptidesInhibitor/AntagonistPharmaceutical PreparationsInnovationCellsResistanceImageLeadSmall Business Innovation Research GrantPeptide LCoupledGrantPhage DisplayCenters For Disease Control And Prevention (U.S.)InfectionViralDrug DiscoveryProteinsAnimal Model
Grant awards (17)
Depot formulation of a D-peptide HIV entry inhibitor$551,835
R01 · FY2019 · AI
Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease$106,814
R43 · FY2019 · DK · contact PI
Preclinical development of a potent D-peptide RSV inhibitor$999,998
R44 · FY2018 · AI · contact PI
Depot formulation of a D-peptide HIV entry inhibitor$571,590
R01 · FY2018 · AI
Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease$216,252
R43 · FY2018 · DK · contact PI
Preclinical development of a potent D-peptide RSV inhibitor$999,998
R44 · FY2017 · AI · contact PI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$894,941
R44 · FY2017 · AI · contact PI
Depot formulation of a D-peptide HIV entry inhibitor$826,272
R01 · FY2017 · AI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$1,000,000
R44 · FY2016 · AI · contact PI
Preclinical development of a potent D-peptide RSV inhibitor$992,263
R44 · FY2016 · AI · contact PI
Highly specific anti-toxin therapies for severe bacterial gut infections$297,401
R43 · FY2016 · AI · contact PI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$1,000,000
R44 · FY2015 · AI · contact PI
Highly specific anti-toxin therapies for severe bacterial gut infections$299,943
R43 · FY2015 · AI · contact PI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$300,000
R43 · FY2013 · AI · contact PI
Protease-resistant D-peptide inhibitors of RSV entry$296,123
R43 · FY2013 · AI · contact PI
Protease-resistant D-peptide Inhibitors of Ebola Virus Entry$300,000
R43 · FY2012 · AI · contact PI
Protease-resistant D-peptide inhibitors of RSV entry$295,945
R43 · FY2012 · AI · contact PI